Karolinska Development AB ser. B (KDEV) - Net Assets
Based on the latest financial reports, Karolinska Development AB ser. B (KDEV) has net assets worth Skr1.04 Billion SEK (≈ $112.44 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr1.05 Billion ≈ $113.34 Million USD) and total liabilities (Skr8.34 Million ≈ $897.73K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Karolinska Development AB ser. B's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr1.04 Billion |
| % of Total Assets | 99.21% |
| Annual Growth Rate | -1.56% |
| 5-Year Change | 7.6% |
| 10-Year Change | 3404.5% |
| Growth Volatility | 192.05 |
Karolinska Development AB ser. B - Net Assets Trend (2007–2025)
This chart illustrates how Karolinska Development AB ser. B's net assets have evolved over time, based on quarterly financial data. Also explore Karolinska Development AB ser. B total assets for the complete picture of this company's asset base.
Annual Net Assets for Karolinska Development AB ser. B (2007–2025)
The table below shows the annual net assets of Karolinska Development AB ser. B from 2007 to 2025. For live valuation and market cap data, see Karolinska Development AB ser. B (KDEV) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr1.04 Billion ≈ $112.44 Million |
-15.65% |
| 2024-12-31 | Skr1.24 Billion ≈ $133.31 Million |
-0.65% |
| 2023-12-31 | Skr1.25 Billion ≈ $134.18 Million |
+0.43% |
| 2022-12-31 | Skr1.24 Billion ≈ $133.60 Million |
+27.84% |
| 2021-12-31 | Skr971.09 Million ≈ $104.50 Million |
+21.35% |
| 2020-12-31 | Skr800.27 Million ≈ $86.12 Million |
-20.59% |
| 2019-12-31 | Skr1.01 Billion ≈ $108.45 Million |
+240.44% |
| 2018-12-31 | Skr296.01 Million ≈ $31.86 Million |
+10.81% |
| 2017-12-31 | Skr267.12 Million ≈ $28.75 Million |
+795.93% |
| 2016-12-31 | Skr29.82 Million ≈ $3.21 Million |
-87.97% |
| 2015-12-31 | Skr247.88 Million ≈ $26.68 Million |
-84.94% |
| 2014-12-31 | Skr1.65 Billion ≈ $177.09 Million |
-12.02% |
| 2013-12-31 | Skr1.87 Billion ≈ $201.28 Million |
-7.60% |
| 2012-12-31 | Skr2.02 Billion ≈ $217.84 Million |
-6.89% |
| 2011-12-31 | Skr2.17 Billion ≈ $233.95 Million |
+26.60% |
| 2010-12-31 | Skr1.72 Billion ≈ $184.80 Million |
-14.07% |
| 2009-12-31 | Skr2.00 Billion ≈ $215.05 Million |
+21.05% |
| 2008-12-31 | Skr1.65 Billion ≈ $177.66 Million |
+19.11% |
| 2007-12-31 | Skr1.39 Billion ≈ $149.15 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Karolinska Development AB ser. B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 367.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr2.70 Million | 0.26% |
| Other Components | Skr2.74 Billion | 261.84% |
| Total Equity | Skr1.04 Billion | 100.00% |
Karolinska Development AB ser. B Competitors by Market Cap
The table below lists competitors of Karolinska Development AB ser. B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SOTKAMO SILVER AB NAM.
F:VSO
|
$29.37 Million |
|
Welcron Company Limited
KQ:065950
|
$29.38 Million |
|
LMS Co. Ltd
KQ:073110
|
$29.38 Million |
|
Churchill Resources Inc
V:CRI
|
$29.38 Million |
|
Tartisan Nickel Corp
F:8TA
|
$29.36 Million |
|
Naga Dhunseri Group Limited
NSE:NDGL
|
$29.30 Million |
|
INOVIQ LTD.
F:EGQ0
|
$29.30 Million |
|
PTL LTD Ordinary Shares
NASDAQ:PTLE
|
$29.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Karolinska Development AB ser. B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,238,723,000 to 1,044,867,999, a change of -193,855,001 (-15.6%).
- Net loss of 193,855,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-193.85 Million | -18.55% |
| Other Changes | Skr-1.00 | -0.0% |
| Total Change | Skr- | -15.65% |
Book Value vs Market Value Analysis
This analysis compares Karolinska Development AB ser. B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.09x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | Skr59.26 | Skr0.29 | x |
| 2009-12-31 | Skr65.54 | Skr0.29 | x |
| 2010-12-31 | Skr44.82 | Skr0.29 | x |
| 2011-12-31 | Skr37.89 | Skr0.29 | x |
| 2012-12-31 | Skr30.47 | Skr0.29 | x |
| 2013-12-31 | Skr34.19 | Skr0.29 | x |
| 2014-12-31 | Skr29.98 | Skr0.29 | x |
| 2015-12-31 | Skr4.13 | Skr0.29 | x |
| 2016-12-31 | Skr0.50 | Skr0.29 | x |
| 2017-12-31 | Skr3.86 | Skr0.29 | x |
| 2018-12-31 | Skr4.09 | Skr0.29 | x |
| 2019-12-31 | Skr12.08 | Skr0.29 | x |
| 2020-12-31 | Skr4.04 | Skr0.29 | x |
| 2021-12-31 | Skr4.90 | Skr0.29 | x |
| 2022-12-31 | Skr4.82 | Skr0.29 | x |
| 2023-12-31 | Skr4.62 | Skr0.29 | x |
| 2024-12-31 | Skr4.59 | Skr0.29 | x |
| 2025-12-31 | Skr3.15 | Skr0.29 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Karolinska Development AB ser. B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1794.79%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.01x
- Recent ROE (-18.55%) is above the historical average (-57.29%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 29.43% | 2601.10% | 0.01x | 1.07x | Skr264.49 Million |
| 2008 | -0.35% | -248.36% | 0.00x | 1.01x | Skr-170.80 Million |
| 2009 | -0.13% | -8.71% | 0.01x | 1.02x | Skr-202.48 Million |
| 2010 | -19.87% | -2407.95% | 0.01x | 1.05x | Skr-502.96 Million |
| 2011 | -20.53% | -3680.44% | 0.00x | 1.25x | Skr-573.56 Million |
| 2012 | -12.75% | -2140.72% | 0.00x | 1.33x | Skr-379.84 Million |
| 2013 | 10.56% | 1983.53% | 0.01x | 1.02x | Skr10.48 Million |
| 2014 | -22.84% | -7471.47% | 0.00x | 1.04x | Skr-540.37 Million |
| 2015 | -425.48% | -35848.84% | 0.00x | 2.48x | Skr-1.08 Billion |
| 2016 | -727.26% | -4045.37% | 0.01x | 14.70x | Skr-219.81 Million |
| 2017 | 67.23% | 7288.76% | 0.00x | 2.48x | Skr152.88 Million |
| 2018 | 10.31% | 992.84% | 0.00x | 2.68x | Skr909.30K |
| 2019 | 65.27% | 19435.85% | 0.00x | 1.16x | Skr556.94 Million |
| 2020 | -48.17% | -14540.78% | 0.00x | 1.11x | Skr-465.50 Million |
| 2021 | 36.44% | 16306.31% | 0.00x | 1.14x | Skr256.74 Million |
| 2022 | -11.68% | -6306.00% | 0.00x | 1.01x | Skr-269.18 Million |
| 2023 | 0.43% | 267.43% | 0.00x | 1.01x | Skr-119.30 Million |
| 2024 | -0.65% | -440.75% | 0.00x | 1.01x | Skr-131.97 Million |
| 2025 | -18.55% | -1794.79% | 0.01x | 1.01x | Skr-298.34 Million |
Industry Comparison
This section compares Karolinska Development AB ser. B's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,054,194
- Average return on equity (ROE) among peers: -81.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Karolinska Development AB ser. B (KDEV) | Skr1.04 Billion | 29.43% | 0.01x | $29.36 Million |
| 2cureX AB (2CUREX) | $74.34 Million | -25.47% | 0.06x | $4.90 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $40.96 Million |
| AcouSort AB (ACOU) | $15.58 Million | -57.51% | 0.12x | $8.97 Million |
| Active Biotech AB (ACTI) | $188.64 Million | -118.73% | 1.64x | $17.19 Million |
| Alzinova AB (ALZ) | $20.63 Million | -16.51% | 0.08x | $4.97 Million |
| AlzeCure Pharma (ALZCUR) | $182.01 Million | -28.02% | 0.03x | $18.18 Million |
| Annexin Pharmaceuticals AB (ANNX) | $18.81 Million | -234.16% | 0.42x | $11.24 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $14.33 Million |
| BioInvent International AB (BINV) | $219.00 Million | -63.86% | 0.22x | $155.44 Million |
| BioArctic AB (publ) (BIOA-B) | $788.68 Million | -15.19% | 0.14x | $2.59 Billion |
About Karolinska Development AB ser. B
KDventures AB is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in th… Read more